Distribution of the CCR5 gene 32-bp deletion in Europe

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 19, Issue 2, 1998, Pages 174-177

  Lucotte, Gérard ^a,b   Mercier, Géraldine ^c  

^a HÔPITAL MAISON BLANCHE   (France)

^b Intl Institute of Anthropology   (France)

^c European Laboratory of Screening   (France)

Author keywords

A32 Allele; CCR5; Distribution in Europe

Indexed keywords

ALLELE; ARTICLE; DELETION MUTANT; EUROPE; GENE FREQUENCY; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; VIRUS MUTATION;

EID: 0031656224     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199810010-00011     Document Type: Article

References (18)

1. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996; 273:1856-62.
2. Ansari-Lari A, Liu XM, Metzker ML, Rut AR, Gibbs RA. The extent of genetic variation in the CCR5 gene. Nature Genet 1997;16:221-2.
3. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77.
4. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-5.
5. Biti R, French R, Young J, et al. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nature Med 1997;3:252-3.
6. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Genet 1996; 2:1240-3.
7. Eugen-Olsen J, Iversen AKN, Garred P, et al. Heterozygosity for a deletion in the CKR5 leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997;11:305-10.
8. Michael NL, Chang G, Louie L, et al. The role of viral phenotype and CCR5 gene defects in HIV-1 transmission and disease progression. Nature Med 1997,3:338-40.
9. Zimmerman PA, Buckler-White A, Alkhatib G, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997;3:23-36.
10. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg J. Global distribution of the CCR5 gene 32-base-pair deletion. Nature Genet 1997;16:100-3.
11. Lucotte G. Frequencies of the CC chemokine receptor 5 Δ32 allele in various populations of defined racial background. Biomed Pharmacother 1997;51:469-73.
12. 1-antitrypsin indicate a single origin for deficiency allele PIZ. Nature 1985;316:79-81.
13. Lucotte G, Hazout S, Loirat F. North-west/south-east gradient in ΔF508 frequency in Europe. Lancet 1991;338:882-3.
14. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJH. Global prevalence of putative hemochromatosis mutations. Med Genet 1997; 34:275-8.
15. Lucotte G, Hazout S. Y-chromosome DNA haplotypes in Basques. J Mol Evol 1996;42:472-5.
16. Libert F, Cochaux P, Beckman G, et al. The Δccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet 1998;7:399-406.
17. Jones G. A history of the Vikings. Oxford: Oxford University Press, 1984.
18. Poser CM. The dissemination of multiple sclerosis: a Viking Saga? A historical essay. Ann Neurol 1994;36(Suppl 2):231-43.